Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer

Clinical Cancer Research

Volumn 11, Issue 24, 2005, Pages 8637-8643

  Psyrri, Amanda ^a,c   Kassar, Mohamad ^a   Yu, Ziwei ^a   Bamias, Aris ^b   Weinberger, Paul M ^a   Markakis, Sonia ^b   Kowalski, Diane ^a   Camp, Robert L ^a   Rimm, David L ^a   Dimopoulos, Meletios A ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL;

ADULT; AGED; ARTICLE; AUTOANALYSIS; AUTOMATED QUANTITATIVE ANALYSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SURVIVAL TIME; TISSUE MICROARRAY;

CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 29344462994     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1436     Document Type: Article

References (31)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Niloff JM, Knapp RC, Schaetzl E, Reynolds C, Bast RC, Jr. CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol 1984;64:703-7.
3. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000; 82:1535-8.
4. Bauknecht T, Kiechle M, Bauer G, Siebers JW. Characterization of growth factors in human ovarian carcinomas. Cancer Res 1986;46:2614-8.
5. Kohler M, Janz I, Wintzer HO, Wagner E, Bauknecht T. The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res 1989;9: 1537-47.
6. Kohler M, Bauknecht T, Grimm M, Birmelin G, Kommoss F, Wagner E. Epidermal growth factor receptor and transforming growth factor α expression in human ovarian carcinomas. Eur J Cancer 1992;28A: 1432-7.
7. Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 2001;93:1375-84.
8. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21: 1980-7.
9. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
10. Saltz LB, Meropol NJ, Loehrer PJ, Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-8.
11. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-7.
12. WHO. WHO handbook for reporting results of cancer treatment. GW, editor. Geneva: WHO, 1979. p. 16-21.
13. Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. Tissue microarray: a new technology for amplification of tissue resources. Cancer J 2001;7: 24-31.
14. Weinberger PM, Yu Z, Haffty BG, et al. Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res 2004;10: 5684-91.
15. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 1987;56:881-914.
16. Sainsbury JR, Farndon JR, Sherbet GV, Harris AL. Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet 1985;1: 364-6.
17. Yu Z, Weinberger PM, Provost E, et al. β-Catenin functions mainly as an adhesion molecule in patients with squamous cell cancer of the head and neck. Clin Cancer Res 2005;11:2471-7.
18. Yu Z, Weinberger PM, Haffty BG, et al. Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin Cancer Res 2005;11:1160-6.
19. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86: 829-35.
20. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-9.
21. Meden H, Marx D, Raab T, Kron M, Schauer A, Kuhn W. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. J Obstet Gynaecol 1995; 21:167-78.
22. Baekelandt M, Kristensen GB, Trope CG, Nesland JM, Holm R. Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer. Anticancer Res 1999;19: 4469-74.
23. Bauknecht T, Kommoss F, Birmelin G, von Kleist S, Kohler M, Pfleiderer A. Expression analysis of EGF-R and TGFa in human ovarian carcinomas. Anticancer Res 1991;11:1523-8.
24. Skirnisdottir I, Seidal T, Sorbe B. A new prognostic model comprising p53, EGFR, tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. Int J Gynecol Cancer 2004;14:259-70.
25. Berchuck A, Rodriguez GC, Kamel A, et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 1991;164: 669-74.
26. Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 2004;14: 1086-96.
27. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-10.
28. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6: 279-86.
29. Kyomoto R, Kumazawa H, Toda Y, et al. Cyclin-D1-gene amplification is a more potent prognostic factor than its protein over-expression in human head-and-neck squamous-cell carcinoma. Int J Cancer 1997; 74:576-81.
30. Lin SY, Makino K, Xia W, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001;3:802-8.
31. Carpenter G. Nuclear localization and possible functions of receptor tyrosine kinases. Curr Opin Cell Biol 2003;15:143-8.